Novolog (NVLG) AI Stock Analysis

Top Page

Novolog

(TASE:NVLG)

Select Model

Rating:50Neutral

Price Target:ILA 88.00▲(4.51% Upside)

Action:reiterated

Date:10/08/26

Moderate financial performance is the primary driver, reflecting revenue gains tempered by margin and cash flow volatility. Short-term technical momentum provides secondary support, while negative P/E limits valuation upside.

Positive Factors

Strong TTM revenue growthThe 56.4% TTM revenue increase indicates stronger recent sales activity and expanding business volume. If maintained, this growth can improve operating leverage, support reinvestment, and strengthen Novolog’s position in medical distribution over the coming quarters.

Negative Factors

Profitability deteriorationThe move to slightly negative net income, alongside compressed gross and operating margins, shows that stronger sales are not currently translating into durable earnings. Thin profitability leaves less room to absorb cost pressure and may constrain reinvestment capacity.

Novolog (NVLG) vs. iShares MSCI Israel ETF (EIS)

Market Cap: ILS 430.16M
Dividend Yield: 4.65%
Average Volume (3M): 599.24K
Price to Earnings (P/E): -647.7
Beta (1Y): 0.75
Revenue Growth: -13.76%
EPS Growth: -103.31%
Country: Israel
Employees: 916
Sector: General
Sector Strength: 55
Industry: Medical - Distribution

Novolog Business Overview & Revenue Model

Company Description

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medica...

Novolog Financial Statement Overview

Summary

Mixed results with 56% TTM revenue growth offset by gross margin compression to 7.6%, volatile profitability with net losses, and inconsistent cash flows, though moderate leverage offers some stability.

Income Statement

47Neutral

Balance Sheet

61Positive

Cash Flow

44Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.81B	1.81B	2.02B	1.64B	1.51B	1.26B
Gross Profit	137.75M	124.09M	180.78M	173.76M	176.15M	148.96M
EBITDA	105.05M	100.75M	149.39M	130.14M	138.53M	115.92M
Net Income	-674.00K	4.12M	39.54M	-42.00M	47.51M	42.32M
Balance Sheet
Total Assets	2.71B	2.15B	3.04B	2.79B	2.43B	2.29B
Cash, Cash Equivalents and Short-Term Investments	204.46M	121.77M	247.60M	232.94M	172.81M	238.71M
Total Debt	171.19M	183.20M	198.47M	215.18M	212.77M	166.81M
Total Liabilities	2.35B	1.78B	2.65B	2.39B	1.97B	1.86B
Stockholders Equity	350.91M	356.85M	368.38M	371.08M	436.00M	424.37M
Cash Flow
Free Cash Flow	71.82M	-34.22M	99.78M	129.06M	63.16M	52.75M
Operating Cash Flow	70.18M	-16.50M	158.52M	200.01M	132.65M	83.39M
Investing Cash Flow	-40.34M	-61.92M	-50.55M	-72.60M	-124.95M	-69.07M
Financing Cash Flow	-48.86M	-46.02M	-94.59M	-67.71M	-72.96M	47.49M

Novolog Technical Analysis

Technical Analysis SentimentNeutral

Last Price84.20

Price Trends

50DMA80.29Positive

100DMA78.21Positive

200DMA93.95Negative

Market Momentum

MACD1.41Positive

RSI51.90Neutral

STOCH25.58Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Neutral. The current price of 84.20 is below the 20-day moving average (MA) of 84.77, above the 50-day MA of 80.29, and below the 200-day MA of 93.95, indicating a neutral trend. The MACD of 1.41 indicates Positive momentum. The RSI at 51.90 is Neutral, neither overbought nor oversold. The STOCH value of 25.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:NVLG.

Novolog Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IL:NVLG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IL:NVLG	50Neutral	ILS 430.16M	-647.69	―	4.65%	-13.76%	-103.31%

* General Sector Average

Performance Comparison

IL:NVLG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IL:NVLG	Novolog (Pharm UP 1966) Ltd.	84.20	-42.16	-33.36%
IL:BONS	Bonus Biogroup	17.70	-3.80	-17.67%
IL:ILX	ILEX Medical Ltd.	4782.00	-1485.05	-23.70%
IL:GEFR	Cannomed Medical Cannabis Industries Ltd.	76.40	-7.60	-9.05%
IL:MDPR	Medipower (Overseas) Public Co. Limited.	490.90	-195.54	-28.49%
IL:EPIT	EPITOMEE MEDICAL LTD	336.30	-409.30	-54.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026

Novolog AI Stock Analysis